# Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** https://moleculinbiotech.com
- **LinkedIn:** https://www.linkedin.com/company/moleculin-llc

## Regulatory record

- **Reports private funds:** No

## About

Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

## Questions

### What is Moleculin Biotech's lead drug candidate?

Moleculin's lead candidate is Annamycin, a next-generation anthracycline designed to treat acute myeloid leukemia and soft tissue sarcoma. It is in Phase 2 clinical trials as of 2025 (per SEC filings and press releases).

### What therapeutic areas does Moleculin focus on?

Moleculin focuses on oncology, specifically drug-resistant cancers, and broad-spectrum antiviral therapies. Its pipeline includes Annamycin for AML and soft tissue sarcoma, plus WP1066 for brain tumors and pancreatic cancer.

## Related profiles

- [Intensity Therapeutics](https://altss.com/profile/intensity-therapeutics-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/moleculin-biotech-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology